---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286160018.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares increased by 3.53% to $11.43 on a mixed trading day, outperforming competitors like Vanda Pharmaceuticals and Fortress Biotech. This marks the third consecutive day of gains for Corbus, although it remains 44.41% below its 52-week high of $20.56. The trading volume was 262,563, surpassing the 50-day average of 261,494. The Dow Jones rose 0.11%, while the NASDAQ fell 0.71%."
datetime: "2026-05-12T21:21:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286160018.md)
  - [en](https://longbridge.com/en/news/286160018.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286160018.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rose 3.53% to $11.43 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.11% to 49,760.56 and the NASDAQ Composite Index falling 0.71% to 26,088.20.

This was the stock's third consecutive day of gains.

Corbus Pharmaceuticals Holdings Inc. closed 44.41% short of its 52-week high of $20.56, which the company achieved on October 20th.

The stock outperformed some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 2.39% to $6.42, Fortress Biotech Inc. (FBIO) rose 0.89% to $2.26, and Viking Therapeutics Inc. (VKTX) fell 1.26% to $31.32.

Trading volume (262,563) eclipsed its 50-day average volume of 261,494.

Data source: Dow Jones Market Data, FactSet. Data compiled May 12, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-12-26 1721ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)